A scoping review of OMOP CDM adoption for cancer research using real world data.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40189628.
- Also identified by DOI 10.1038/s41746-025-01581-7 and PMC identifier 11973147.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Observational Medical Outcomes Partnership (OMOP) common data model (CDM) supports large-scale research by enabling distributed network analyses. However, the breadth of its adoption in cancer research is not well understood. We conducted a scoping review to describe the adoption of the OMOP CDM in cancer research. A total of 49 unique articles were included in the review, with 30 on the data analysis theme, and 20 on the infrastructure theme. This review highlighted that while the OMOP CDM ecosystem has enabled successful data support for cancer research, particularly for collaborative studies, ongoing model development and iterative improvement remain needed to fulfill additional research data needs. Expanding disease sites, specifically for rare cancers, integrating more diverse types of data sources, improving data quality, adopting advanced analytics methodology, and increasing multisite evaluations serve as important opportunities to facilitate secondary usage of observational data in future cancer research.